FDA cleared IND application to enable phase II trial of ViralClear’s merimepodib to treat adult patients with advanced COVID-19 to proceed
| | | |

FDA cleared IND application to enable phase II trial of ViralClear’s merimepodib to treat adult patients with advanced COVID-19 to proceed

On May 18, 2020, BioSig Technologies and its subsidiary, ViralClear Pharmaceuticals, announced the U.S. Food and Drug Administration…

ViralClear submitted in vitro data on Merimepodib and Remdesivir synergistic activity against COVID-19 novel Coronavirus to peer-reviewed journal
| | |

ViralClear submitted in vitro data on Merimepodib and Remdesivir synergistic activity against COVID-19 novel Coronavirus to peer-reviewed journal

On Apr. 30, 2020, BioSig Technologies announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination…